HVC Group All RSS

Move to the new office

2010-02-14T09:34:49Z

Hokkaido Venture Capital, Inc. announced that its Tokyo office will move in order to strengthen the efforts of regional developments and incubation businesses. Business operation at the new office will start on 15th February.

◆Tokyo office of Hokkaido Venture Capital, Inc.

Add: Chiyoda Platform Square 1223, 3-21 Kanda-Nishikicho, Chiyoda-ku, Tokyo 101-0054 Japan
Tel: +81-3-3233-1611
Fax: +81-3-3233-1613

◆Headquarters of HVC Global Investment, Inc.

Add: Chiyoda Platform Square 1223, 3-21 Kanda-Nishikicho, Chiyoda-ku, Tokyo 101-0054 Japan
Tel: +81-3-3233-1612
Fax: +81-3-3233-1613

【ACCESS】

It sees with a big map.

By subway
Tokyo Metro Tozai Line: 2-min. walk from Exit 3b of Takebashi Sta.
Tokyo Metro Hanzomon Line: 7-min. walk from Exit A9 of Jimbo-cho Sta.
Tokyo Metro Marunouchi Line: 8-min. walk from Exit C2b of Ote-machi Sta.

By JR lines
12-min. walk from West Entrance of Kanda Sta.

"The 5th HVC Business Presentation" to be held on Oct. 9th, 2009.

2009-10-05T00:14:14Z

HVC, Inc. and HVC Group will hold "The 5th HVC Business Presentation" on Oct. 9th, 2009. We are preparing 11 business presentation by HVC's portfolio companies and 2 keynote speeches by business experts.

We are looking forward to seeing their business presentation and making communications.

＜Event Outline＞
◆Date：Oct. 9th(Fri), 2009
　　　　　　・Presentation: 9：30～18：45
　　　　　　・Party:19：00～20：30

◆Venue：White Cube Sapporo (map)

◆Contact:Junichi Miura
　　　　　TEL：+81-11-738-3838　E-mail is here.

＜Keynote Speech＞
（1）"Exit strategies after global financial crisis"

Speaker：　Mr. Gunji Sakamoto
　　　　　　　　Managing Director
　　　　　　　　Japan Economic Pulse Co., Ltd.

（2）"Potential for venture businesses in Hokkaido and key factors for business success"

Speaker：　Mr. Kiichi Otani
　　　　　　　　President and Representative Director
　　　　　　　　AIN PHARMACIEZ INC.

＜Business area of participant companies＞
（1）GP Biosciences Ltd.
Development, manufacturing, and sales of lectin microarray, software, scanner, and other devices that related to all-round glycan analysis

（2）NB Health Laboratory Co. Ltd
Drug discovery service and research and development of drug candidates for age-related diseases

（3）3-D Matrix Japan, Ltd.
Business development of a synthetic self-assembling peptide biomaterial called Pure Matrix™ that is to be used as regeneration medicine, bone matrix, etc.

（4）Laser Systems Inc.
Development, manufacturing, and sales of laser products

（5）Atmark Techno, Inc.
Development, manufacturing, and distribution of embedded LINUX boards, etc.

（6）Hokkaido Needs, Co., Ltd.
Sale and rental of fishery equipments and manufacture and sale of ice for fishery

（7）BIG BE, Inc.
Operation of shopping websites that sales toys and games, etc.

（8）Hokkaido Wine K. K.
Production and distribution of wine made from 100% Hokkaido-grown grapes

（9）ECO ERC, Inc.
Manufacturing and sales of biodiesel fuel(BDF)

（10）Huens, Co. Ltd.
Design and construction of wastewater treatment systems with ozone and related systems

（11）Econos K. K.
Operations of BOOK OFF and HARD OFF and other franchised second-hand shops

Four HVC's portfolio companies participate as exhibitors in the one of the largest exhibition "Bio Japan 2009" to be held Oct. 7th to 9th, 2008 at PACIFICO YOKOHAMA.

2009-10-04T08:57:33Z

Four HVC's portfolio companies participate as exhibitors in the one of the largest exhibition "Bio Japan 2009" to be held on Oct. 7th to 9th, 2008 at Pacifico Yokohama.

We look forward to seeing you at the exhibition booths and their business presentations.

Date：　Oct.7th(Wed) -9th(Fri), 2009　10：00～17：00(Tentative)
Venue：　Pacifico Yokohama (map)

Click on the names of the companies below to link to the websites.

◆GP Biosciences Ltd.

＜Seminar＞
・Date： Oct. 7th 13:30-16:30
・Venue： F-202
・Title of seminar： The Fourth Forum of Glyco-innovation and Industrial Technology
・Speaker： Masao Yamada
                 GP Biosciences Ltd.
                 Glycan Profiling System Division
                 Executive Director & CTO

◆GenoLac BL Corporation

＜Exhibition booth＞
・Booth No.：A306

＜Presentaiton＞
・Date： Oct 8th 14：00-14：20
・Venue： Business Partnering B
・Speaker：Tomomitsu Sewaki
                 President GenoLac BL Corporation
・Title：Development of Mucosal Vaccine Candidates Using a Novel Lactic acid bacteria Display System(Clinical Application for HPV Therapeutic Vaccine)

◆GLab Pathology Center Co., Ltd

＜Exhibition booth＞
・Booth No.：A703　（in the booth of Hokkaido Bio Technology Induster Cluster Forum)

＜Presentation＞
・Date：Oct 7, 14:00 - 14:20
・Venue：Business Partnering B
・Speaker：Tomohisa Maruyama
                GLab Pathology Center Co., Ltd
                Tokyo Desk, Department of Advanced Medical Research and Development
・Title：Advancement of "Personalized Medicine", "Drug Development", and "PGx" by the best use of pathology and molecular pathology technology

◆NB Health Laboratory Co.Ltd.

＜Exhibition booth＞
・Booth No.：B200　（in the booth of Yokohama/Kanagawa Pavilion）

＜Presentation＞
・Date：Oct. 7&9, 10：40-11：10
・Venue：B200　（in the booth of Yokohama/Kanagawa Pavilion）
・Speaker：NB Health Laboratory Co.Ltd.
　　　　　　　HyphaGenesis Co., Ltd
　　　　　　　PharmaDesign, Inc.

CanBas gets listed on the TSE Mothers

2009-09-17T10:04:20Z

CanBas Co., Ltd. ,one of our portfolio companies, today gets listed on the Tokyo Stock Exchanges Mothers.

＜Related Information＞
・Link to the website of CanBas Co., Ltd. is here.
・Link to the list of our portfolio companies is here.

Ikkei Matsuda will make the speech at "Globalizing Japanese Startups" on September 9, 2009.

2009-09-03T02:17:50Z

Ikkei Matsuda, President of Hokkaido Venture Capital, Inc., will make the speech at "Globalizing Japanese Startups" held on September 9, 2009.

Main discussion topics of this semnar are as follows:
・how entrepreneurships and venture capital is different outside Japan
・why you should think global from day one when starting a new venture

And, GP Biosciences Ltd., one of the portfolio companies of Hokkaido Venture Capital, Inc., will make the presentation about its business outline and strategy, etc.

＜Seminar Outline＞
◆Date：　Wednesday, 09 Sep 2009, 7:00 PM ～9:00 PM

◆Venue：　ITOCHU Corporation Tokyo HQ 10th ｆl.
　　　　　　　　（5-1, Kita-Aoyama 2-chome, Minato-ku, Tokyo 107-8077）

◆Fee：　Free of charge

◆Registration：　Please e-mail to the organizer.

More information is here.

＜Related Information＞
・Link to the official website of The Indus Entrepreneurs(TiE)-Tokyo is here.
・Link to the official website of GP Biosciences Ltd. is here.

Ikkei Matsuda will deliver a keynote speech at the "The 2nd China Cleantech Industry Investment Summit" on June 5, 2009.

2009-05-21T18:47:03Z

Ikkei Matsuda, President of Hokkaido Venture Capital, Inc., will deliver a keynote speech at "the 2nd China Cleantech Industry Investment Summit" held on June 5,2009.

Title and schedule of Matsuda's speech are as follows:
- Speech Title: "Investment in CleanTech in Japan"
- Time and Date: Friday, June 5, 2009, from 13:55 to 14:10
- Venue: Renaissance Beijing Capital Hotel

< Related Information >
- Link to the official website of the "The 2nd China Cleantech Industry Investment Summit" is here (in English ver./ in Chinese ver.).
- Link to official leaflet of the "The 2nd China Cleantech Industry Investment Summit" is here. (a PDF file in Chinese and English, 1.0 MB)
- Link to the website of the "Hokkaido changchenghui" is here (in Chinese).
- Link to the website of the "Japan Venture Capital Association(JVCA)" is here (in English).

Announcement

2009-02-05T10:03:04Z

Hokkaido Venture Capital, Inc. and HVC Strategic Research Institute, Inc. (hereinafter referred to as "HVC GROUP") are committed to protecting information that personally identifies customers (hereinafter referred to as "Private Information"), and each member of HVC GROUP is to be responsible for appropriate information management and strives for the effective enforcement of this policy to fulfill the expectations that our customers including shareholders, fund investors, and portfolio companies have on us.Hokkaido Venture Capital, Inc. and HVC Strategic Research Institute, Inc. (hereinafter referred to as "HVC GROUP") are committed to protecting information that personally identifies customers (hereinafter referred to as "Private Information"), and each member of HVC GROUP is to be responsible for appropriate information management and strives for the effective enforcement of this policy to fulfill the expectations that our customers including shareholders, fund investors, and portfolio companies have on us.　Announce

Kringle Pharma and Maruho Agreed to Conclude an Option Agreement for ChronSeal®

2009-01-28T14:52:00Z

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, "KRINGLE") proudly announces that it has reached to a basic agreement with Maruho Co., Ltd. (Head office located in Osaka; President & CEO: Koichi Takagi, "MARUHO") to enter into an option agreement for ChronSeal®. A multi-center phase I/II clinical trial of ChronSeal® is currently underway for the subjects with venous leg ulcers in Norway and Sweden (refer to our press releases dated 3 December 2008 and 28 January 2009).

Link to the website of press release (28 January 2009) from Kringle Pharma, Inc. is here.

Kringle Pharma Commences a Phase I/II Clinical Trial in Sweden on ChronSeal®, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers

2009-01-28T14:44:35Z

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, "KRINGLE") is proud to announce that the clinical trial application of ChronSeal® to the Swedish authority, Medical Products Agency (MPA), dated 23 December 2008 was approved on 23 January 2009. Having its approval granted by the authority, KRINGLE will conduct a phase I/II clinical trial of ChronSeal® in Sweden.

Link to the website of the press release(28 January 2009) from Kringle Pharma, Inc. is here.

Hokkaido VC supports the "Workshop on Italy- Hokkaido Bilateral Cooperation in Innovative ICT" to be held on Dec. 4, 2008.

2008-12-01T13:03:47Z

Hokkaido Venture Capital, Inc. supports the "Workshop on Italy-Hokkaido Bilateral Cooperation in Innovative ICT" to be held on December 4th, 2008. This workshop is hosted by the Embassy of Italy in Japan, and the workshop programs are jointly organized by Hokkaido University and Politecnico di Torino (Torino University of Technology).

This workshop has stemmed from the MOU (Memorandum of Understanding) for the tripartite alliance signed in January 2007 among Torino Wireless Foundation; then-Sapporo Region Knowledge Cluster Headquarters for Sapporo IT Carrozzeria, Knowledge Cluster Initiative by MEXT; and Hokkaido Venture Capital, Inc.

< Workshop Outline >
[Venue]
Hotel Polestar Sapporo (North 4, West 6, Chuo-ku, Sapporo)

[Time & Date]
9:30 - 16:30, Thursday, December 4th, 2008

[Admission Fee]
Free of charge

[Organizer]
Embassy of Italy, Japan

[Co-organizers]
Hokkaido Government, Torino Chamber of Commerce, Sapporo Chamber of Commerce and Industry

[Academic Organizers]
Hokkaido University, Politecnico di Torino

[Supported by]
Torino Wireless Foundation, NOASTEC, Istituto Superiore Mario Boella, Knowledge Cluster Bio-S, TTS Italia, ITS Japan, METI Hokkaido, Hokkaido ITS Promotion Forum, Sapporo IT Front, Hokkaido Venture Capital, Inc., Hokkaido Information and Communication Technology Association, City of Sapporo

[Assisted by]
Sapporo International Communication Plaza Foundation

< Related Information >
Link to the Hokkaido University website for events is here.
Link to leaflet of the workshop (a PDF fine, 812 KB) is here.
Link to the workshop program (a PDF file, 1.1 MB) is here.

< Related Articles in the Past >
"Hokkaido VC cooperates in "E-wine" service demonstration by Torino Wireless Foundation." (Mar. 22, 2007)
"Hokkaido VC signed an MOU for alliance with Torino Wireless Foundation." (Jan. 26, 2007)

CBP501 Enters Phase II Trials for the Treatment of Malignant Pleural Mesothelioma

2008-11-10T14:54:37Z

CanBas Co., Ltd. (Numazu, Shizuoka, "CanBas") and Takeda Pharmaceutical Company Limited (Osaka, "Takeda") together with its wholly-owned subsidiary Millennium: The Takeda Oncology Company (Cambridge, "Millennium") today announced the advancement of CBP501 into Phase II trials for the treatment of patients with malignant pleural mesothelioma. CBP 501 induces cancer cell death through a mechanism of action that blocks the ability of cancer cells to transition through the cell cycle. Data from the Phase I study indicates that when combined with selected chemotherapeutic drugs, CBP501 appears to enhance the anti-cancer cytotoxic activity of these established treatments.

Hokkaido VC starts recruiting new graduates of 2008.

2008-10-23T13:28:56Z

Hokkaido Venture Capital, Inc. is now accepting applications for the position of venture capitalists from those who are going to graduate from universities or completing master or doctor courses at the end of 2008 academic year, which is March 2009 in Japan.

-Application Guidelines-
[Requirements]
The applicant must be a student graduating from a university or completing a master or doctor course either in Japan or abroad by the end of March 2009. Students of any major can apply.

[Language Skills]
Reading and writing skills in Japanesee

[Job title]
Venture Capitalist

[Number of vacancy]
1 or 2

[Work location]
Headquarters in Sapporo, Hokkaido, Japan

[To apply]
Please e-mail your resume with a cover letter specifying the reason to apply, to the company's personnel department.

* Staff of HVC Group include alumni of:
Keio University, Hokkaido University, Graduate School of Hokkaido University, Waseda University, Graduate School of Otaru University of Commerce, King's College London, INSEAD, Harvard University Business School, Graduate School of Meiji University, the University of Tokyo, Tokyo Institute of Technology, Tokyo University of Pharmacy and Life Science, Graduate School of Tokyo University of Science, Graduate School of Kyoto University and others. (listed in random order)

Announcement of the "Seminar on Starting up Hokkaido Bio-business" on Oct. 12, 2007 and "Bio-business Skill Enhancement Course" (a series of four classes, starting from Oct. 12, 2007)

2008-10-02T13:42:40Z

The markets for functional food and pharmaceutics have recently enlarged rapidly due to the increased aging population, the spread of lifestyle-related diseases, and increased health-consciousness. Hokkaido, abundant in primary products and with a number of researchers with numerous technological seeds, is expected to make great strides in these health-related markets.

In the Seminar on Starting up Hokkaido Bio-business on October 12, 2007, Dr. Yoshiharu Matahira with Yaizu Suisankagaku Industry Co., Ltd., headquartered in Yaizu City in Shizuoka, will first tell us how a local food manufacturing company had transformed itself into a marine biotech company. Then Dr. Daisaku Okamoto with Shokubutsu Ikushu Kenkyujo, a plant breeding research institute that spun off from Hokkaido University will deliver a speech on the possibilities of bio-business in Hokkaido. This institution received in June the JANBO's New Business Creation Award. Later in the seminar, a panel discussion is planned on the issues and development strategy of biotech-related agriculture and marine areas.
* JANBO: Japan Association of New Business Incubation Organization

The "Bio-business Skill Enhancement Course" (a series of four classes starting on October 12, 2007) will focus on the development and enhancement of the skills needed for developing and implementing strategies for biotech ventures in Hokkaido. Each class features lectures, case studies, and discussions among attendants - a practical exercise for solving various business issues. Small class starting from the introduction is suitable also for potential biotech institutions.

From HVC group, Dr. Ikkei Matsuda and Dr. Atsumi Tobitani will attend as lecturers.

Link to the organizer, Sapporo Biz Cafe's website (in Japanese) is here.

< Contact on this article >
Mr. Saito , Bio-business Section, Sapporo Biz Cafe
TEL: +81-11-210-6516 FAX: +81-11-200-3324 E-mail: sanka@tri-b.co.jp

Articles by Dr. Katsuhiko Ito carried in the "NIKKEI BIOTECH ON-LINE" ranked top and second in the number of viewers.

2008-09-26T13:32:16Z

The two articles written by Dr. Katsuhiko Ito of Hokkaido Venture Capital, Inc., to the September 22, 2008 issue of the NIKKEI BIOTECH (Nikkei Biotechnology & Business) were ranked at the top and the second in the number of viewers for its online version called NIKKEI BIOTECH ON-LINE.

Dr. Ito writes a series of articles under "Research on Product Pipelines" monthly to NIKKEI BIOTECH, in addition to his contribution, the "Research on Product Pipelines in Pharmaceutical Industry" in the Nikkei Biotechnology & Business Almanac.

Hokkaido Venture Capital, Inc. invests, and assists in the development of technology-based ventures, after going through the process of precise technical evaluation from the perspective of technical experts while giving full attention to the trends of the market and the major players in the industry. Also HVC Group provides advices on business and partnership strategies for technology-based ventures and also provides consultation services for large corporations who seek technology transfer from venture companies.

-Related Information-
Link to the homepage of the website for NIKKEI BIOTECH ON-LINE is here. (in Japanese)

-Related Articles in the Past-
One of the HVC and HVC-GI's portfolio companies in US, Tacere Therapeutics, enters collaboration and license agreement with Pfizer to develop and commercialize RNAi Hepatitis C drug. (Jan. 08, 2008)
Gene Techno Science Co., Ltd., one of the Hokkaido VC's portfolio companies, announced a licensing agreement with Kaken Pharmaceutical Co., Ltd. (Jul. 04, 2007)

Akiyoshi Shimamura, President of Hokkaido Wine K. K., a portfolio Company of Hokkaido VC, published a book entitled "Absolute 'Domestic Production' Policy - What the Food Maker Should Be"

2008-09-25T13:35:41Z

Mr. Akiyoshi Shimamura published a book entitled "Absolute 'Domestic Production' Policy - What the Food Maker Should Be" from TOYO KEIZAI INC. Mr. Shimamura is the president of Hokkaido Wine K. K., headquartered in Otaru, Hokkaido, which produces and distributes wine made only from domestic grapes.

-Publication Information-
Title: "Absolute 'Domestic Production' Policy - What the Food Maker Should Be"
Author: Akiyoshi Shimamura, president of Hokkaido Wine K. K.
Publisher: TOYO KEIZAI INC.
Release date: Fri., September 12, 2008
Price: JPY1,575 (including JPY75 tax)
Language: Japanese

Contents:
Chapter 1: The hidden mechanism of frequently occurred food fraud and scandals.
Chapter 2: "Phony domestic" products prevailing in wine industry.
Chapter 3: Hindrance to "domestic agricultural products."
Chapter 4: "Domestic production" policy vitalizes the region.
Chapter 5: Becoming the food maker targeting at "Domestic production."

-Related Information-
Link to the website of this publication at amazon.co.jp is here. (in English)
Link to the website of Hokkaido Wine K. K. is here. (in Japanese)